A case of glassy cell carcinoma of the uterine cervix effectively responding to chemotherapy with paclitaxel and carboplatin

Hirashima, Yasuyuki; Kobayashi, Hiroshi; Nishiguchi, Tomizou; Miura, Katsutoshi; Kanayama, Naohiro

doi:10.1097/00001813-200108000-00010

Cited by 12 publications

(12 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The other two women with adjuvant PC chemotherapy are alive in disease‐free state in for more than 4.5 years. Some reports showed that PC chemotherapy is effective for primary and recurrent GCC of the cervix 8–11 . Nasu et al .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Adjuvant combined paclitaxel and carboplatin chemotherapy for glassy cell carcinoma of the uterine cervix: Report of three cases with clinicopathological analysis

Takahashi¹,

Sasaki

Mogami

et al. 2011

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Glassy cell carcinoma of the uterine cervix (GCC) is a rare form of cervical carcinoma that is characterized by aggressiveness and poor prognosis. We reviewed a variety of clinicopathological features, treatment strategies, and outcomes in three women with GCC. The three patients were successfully treated by radical hysterectomy with pelvic/para-aortic lymphadenectomy. The patients had stage Ib1, stage IIa, and stage Ib2 tumors without lymph node metastases. A 44-year-old woman with stage Ib1 tumor did not undergo adjuvant chemotherapy or radiation therapy. She had recurrent pelvic tumors 12 months after surgery, and died 6 months after the recurrent disease. The histological findings of her cervix, which were different from the other two patients, did not show the marked infiltration of eosinophils. The other two patients with stage Ib2 and IIa tumors underwent adjuvant chemotherapy with paclitaxel and carboplatin, and had disease-free survival for 4.5 and 9 years. We think that all patients with GCC of stage Ib1 or more should undergo adjuvant chemotherapy of paclitaxel and carboplatin or other adjuvant therapies.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Some reports showed that PC chemotherapy is effective for primary and recurrent GCC of the cervix. [8][9][10][11] Nasu et al reported a case of glassy cell carcinoma treated using conventional radiation therapy and six courses of triweekly PC chemotherapy. 12 We also considered that adjuvant PC chemotherapy is effective for GCC.…”

Section: Discussionmentioning

confidence: 99%

Adjuvant combined paclitaxel and carboplatin chemotherapy for glassy cell carcinoma of the uterine cervix: Report of three cases with clinicopathological analysis

Takahashi¹,

Sasaki

Mogami

et al. 2011

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

“…Multimodal therapy should be used for GCC because of the occurrence of the disease in younger patients, its rapid progression, and its poor prognosis 9 . Piura et al.…”

Section: Discussionmentioning

confidence: 99%

Multimodal treatment for glassy cell carcinoma of the uterine cervix

Nasu

Takai

Narahara

2009

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Glassy cell carcinoma of the uterine cervix is a rare form of cervical cancer that is characterized by aggressiveness and poor prognosis because of its rapid growth, its frequent distant metastases, and its relative resistance to conventional treatment modalities including surgery, radiotherapy, and chemotherapy. We report here a case of glassy cell carcinoma of the uterine cervix that was successfully treated with radical surgery followed by radiation therapy and combination chemotherapy with paclitaxel and carboplatin. A 30-year-old primigravid Japanese woman was admitted to our hospital to be treated for stage IIb uterine cervical cancer. She was treated with radical hysterectomy with pelvic and paraaortic lymphadenectomy. The pathological diagnosis of the surgical specimen was glassy cell carcinoma of the uterine cervix with metastases to the right obturator lymph nodes and left external iliac lymph nodes. The surgical staging of the disease was pT2b, pN1, and pM0. Subsequently, she was treated using conventional radiation therapy (50Gy by whole pelvic radiation) and six courses of tri-weekly chemotherapy with paclitaxel (180 mg/m(2)) and carboplatin (area under the curve of 6.0 mg min/mL calculated using the Calvert formula). The patient is alive, without evidence of recurrence, 30 months following the surgery. It is suggested that multimodal therapy with radical surgery, radiation, and combined chemotherapy should be used to treat glassy cell carcinoma of the uterine cervix. Our multimodal treatment protocol may be one of the treatment options for this aggressive disease.

show abstract

“…TJ therapy was selected as the regimen of NAC because Matsuura et al [11] and Hirashima et al [15] showed the usefulness of these agents against recurrent GCC. TJ therapy was selected as the regimen of NAC because Matsuura et al [11] and Hirashima et al [15] showed the usefulness of these agents against recurrent GCC.…”

Section: Discussionmentioning

confidence: 99%

“…We selected the monthly schedule because the TJ therapy efficacy for GCC was reported with a monthly schedule [11,15] and there are some reports in which an NAC monthly schedule for cervical cancer was useful [17][18][19]. a monthly or weekly schedule.…”

Section: Discussionmentioning

confidence: 99%

A case of glassy cell carcinoma of the uterine cervix that responded to neoadjuvant chemotherapy with paclitaxel and carboplatin

Takekuma¹,

Hirashima²,

Takahashi³

et al. 2006

Anti-Cancer Drugs

Self Cite

View full text Add to dashboard Cite

Glassy cell carcinoma of the uterine cervix is a rare tumor, and has a poor prognosis because of its aggressive clinical behavior and resistance to radiotherapy and chemotherapy. We report a case of bulky glassy cell carcinoma of the uterine cervix that effectively responded to paclitaxel and carboplatin in a neoadjuvant setting. The patient was a 30-year-old woman who became aware of vaginal bleeding and was referred to our hospital because of a cancerous tumor of the uterine cervix. Physical examination showed the cervical tumor to be approximately 8 cm in diameter with no involvement of the parametrium or vagina. The biopsy results suggested a diagnosis of glassy cell carcinoma. The final diagnosis was glassy cell carcinoma of the uterine cervix, stage 1b2. Neoadjuvant chemotherapy with paclitaxel and carboplatin was administered for downstaging. The response rate was 67.9% (partial response) under magnetic resonance imaging, and elevated serum cancer-related antigen 125 (119 U/ml) and squamous cancer cell antigen (34 ng/ml) were reduced to 34 U/ml and 3.3 ng/ml, respectively. Following neoadjuvant chemotherapy, she underwent radical hysterectomy and adjuvant chemotherapy with the same regimen. The clinical course was very good. We speculate that glassy cell carcinoma is a sensitive tumor to paclitaxel and carboplatin. Further evaluation concerning diagnosis and treatment, however, is needed to improve the prognosis of patients with glassy cell carcinoma.

show abstract

A case of glassy cell carcinoma of the uterine cervix effectively responding to chemotherapy with paclitaxel and carboplatin

Cited by 12 publications

References 8 publications

Adjuvant combined paclitaxel and carboplatin chemotherapy for glassy cell carcinoma of the uterine cervix: Report of three cases with clinicopathological analysis

Adjuvant combined paclitaxel and carboplatin chemotherapy for glassy cell carcinoma of the uterine cervix: Report of three cases with clinicopathological analysis

Multimodal treatment for glassy cell carcinoma of the uterine cervix

A case of glassy cell carcinoma of the uterine cervix that responded to neoadjuvant chemotherapy with paclitaxel and carboplatin

Contact Info

Product

Resources

About